CTLA4 and hepatocellular carcinoma: Because of the differences in timing, location, and nonoverlapping effects between the PD-1/PD-L1 and CTLA-4 signaling pathways, combination therapy concurrently targeting these two immune checkpoints may achieve the potential synergistic effects in the treatment of HCC.